Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2026)

Amylyx Pharmaceuticals has reported Retained Earnings for 6 years, with the latest figure at -$836.1 million in Q2 2026.

• On a quarterly basis, Retained Earnings fell 22.23% year-over-year to -$836.1 million in Q2 2026; TTM through Jun 2026 was -$836.1 million, a 22.23% decrease from a year earlier, with the FY2025 full-year figure at -$751.4 million, down 23.86% from the prior year.
• Retained Earnings was -$836.1 million for Q2 2026 at Amylyx Pharmaceuticals, down from -$792.7 million in the prior quarter.
• The five-year high for Retained Earnings was -$203.7 million in Q1 2022, with the low at -$836.1 million in Q2 2026.
• Average Retained Earnings over 5 years is -$497.0 million, with a median of -$460.1 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings plunged 127.29% in 2022, then grew 13.91% in 2023.
• Over 5 years, Retained Earnings stood at -$354.2 million in 2022, then advanced by 13.91% to -$304.9 million in 2023, then sank by 98.95% to -$606.7 million in 2024, then fell by 23.86% to -$751.4 million in 2025, then slipped by 11.27% to -$836.1 million in 2026.
• The last three Retained Earnings figures came in at -$836.1 million (Q2 2026), -$792.7 million (Q1 2026), and -$751.4 million (Q4 2025), per Business Quant data.